Recent Updates — BYSI

BeyondSpring Inc. completed the closing of its Share Purchase and Collaboration Agreement with Biolin Investment Limited on September 30, 2026. The company sold its entire interest in BeyondSpring Ltd., which indirectly holds Dalian Wanchunbulin Pharmaceuticals (Bulin), to Biolin. No cash was paid; consideration consists of an exclusive license to clinical data from the China portion of the DUBLIN-4 Phase 3 trial for Plinabulin and Biolin's commitment to fund Bulin's conduct of that trial. The transaction includes a clawback provision requiring equity return if patient enrollment targets are not met. Pro forma financials reflect a preliminary estimated gain on disposition of $53,677 thousand, though this amount is excluded from continuing operations as it pertains to discontinued businesses. BeyondSpring Inc. operates in the biopharmaceutical industry, focusing on the development of oncology therapies.

BeyondSpring Inc. received a written notification from Nasdaq on September 29, 2026, stating it no longer complies with the Market Value of Listed Securities (MVLS) requirement because its MVLS fell below $35 million for 30 consecutive business days. The company has an 180-day compliance period until March 29, 2027, to restore its MVLS to at least $35 million for ten consecutive business days. Failure to regain compliance by the deadline will result in a delisting notification, though the company may appeal. This event poses significant risk to the company's listing status and liquidity but does not immediately affect operations or trading. BeyondSpring Inc. operates in the biopharmaceutical industry, focusing on the development of cancer treatments.

BeyondSpring Inc. announced that the FDA granted Fast Track designation for Plinabulin combined with docetaxel in post-immunotherapy non-squamous NSCLC patients without actionable genomic alterations. Concurrently, the company entered into a Share Purchase and Collaboration Agreement to sell its wholly owned subsidiary BeyondSpring Ltd., which holds interests in Chinese subsidiary Dalian Wanchunbulin Pharmaceuticals Ltd., to Biolin Investment Limited for no cash consideration. In exchange, Biolin will fund the China portion of the global Phase 3 DUBLIN-4 trial, expected to enroll approximately 221 patients, representing roughly half of the total planned enrollment of 442 patients. The transaction aims to substantially reduce BeyondSpring's cash requirements while securing access to clinical data for its registration strategy. Additionally, BeyondSpring established an at-the-market equity offering program allowing it to sell up to 9,200,000 ordinary shares through Citizens JMP Securities LLC with a commission of up to 3.0%. BeyondSpring Inc. is a clinical-stage biopharmaceutical company developing innovative cancer therapies.

BeyondSpring Inc. received a written notification from Nasdaq on September 17, 2026, indicating non-compliance with the minimum bid price requirement because its ordinary shares closed below $1.00 for 30 consecutive business days. The company has an 180-day compliance period until March 16, 2027, to restore the share price to at least $1.00 for ten consecutive trading days. Failure to regain compliance may result in delisting or a request for an additional extension. This event does not immediately affect business operations, but the company is evaluating options to meet listing standards. BeyondSpring Inc. operates in the biotechnology industry, focusing on the development of cancer treatments.

BeyondSpring Inc. reported financial results for the quarter ended June 30, 2026, posting a net loss of $1.8 million compared to $1.9 million in the prior year period. Research and development expenses remained flat at $1.0 million, while general and administrative expenses decreased by $0.1 million to $0.8 million due to lower legal and consulting costs. Cash, cash equivalents, and short-term investments declined to $6.5 million from $12.6 million as of December 31, 2025. The company highlighted clinical data for Plinabulin presented at ASCO 2026 and AACR 2026, supporting its confirmatory Phase 3 DUBLIN-4 study in non-squamous NSCLC. Additionally, BeyondSpring announced a leadership transition effective July 1, 2026, appointing Min Qiu as CEO, Dr. Jiangwen (Jen) Majeti as Vice Chairman, and Na Li as CFO to focus on advancing the DUBLIN-4 program. BeyondSpring Inc. is a clinical-stage biopharmaceutical company developing therapies for cancer.